乙型肝炎病毒X蛋白单克隆抗体的制备及肝癌组织中相应抗原的检测

应用基因工程技术制备的１７０００乙型肝炎病毒（ＨＢＶ）Ｘ蛋白（ＨＢｘＡｇ）免疫动物，成功地制备了抗－ＨＢｘ单克降抗体，以此抗体对原发性肝癌（ＨＣＣ）组织、慢性活动性肝炎（ＣＡＮ）肝组织行相应抗原检测，并同时进行乙型肝炎表面抗原（ＨＢｓＡｇ）及乙型肝炎病毒核心抗原（ＨＢｃＡｇ）的检测。在ＨＣＣ标本中ＨＢｘＡｇ在癌内及癌周肝组织中的阳性率分别为５６％及４８％，ＨＢｓＡｇ为１６％及７４％。ＨＢｃＡｇ仅见于癌周，阳性率为１８％。在ＣＡＨ标本中，ＨＢｘＡｇ、ＨＢｓＡｇ、ＨＢｃＡｇ阳性率分别为６．６％、７３．３％及０。血清ＨＢｓＡｇ阳性ＨＣＣ标本中，ＨＢｘＡｇ的检出率为８２．３％、明显高于血清ＨＢｓＡｇ阴性标本（５４．５％）。结果显示。ＨＢｘＡｇ在ＨＣＣ标本中的表达是ＨＢＶ标志物中最活跃的。ＨＢｘＡｇ的表达不依赖于ＨＢＶ的复制，可能是ＨＢＶＸ基因同宿主细胞基因整合后的产物，ＨＢｘＡｇ在ＨＣＣ标本中的活跃表达为抗－ＨＢｘ抗体作为ＨＣＣ导向治疗载体提供了依据。

Preparation of monoclonal antibody directed againsthepatitis B virus X protein and detection of reactiveantigen in hepatocellular carciuoma

mouse monoclonal antibody directed againsthepatitis B virus (HBV) X protein (HBxAg) was pre-pared. The antibody was used to sereen byimmunogistochemistry 50 liver tissue sections frompatients with hepatoeellular carcinoma (HCC), and 15patients with chronic active hepatitis (CAH). 28 of50(56%). samples were HBxAg positive in tumor tis-sues. The positive rates of HBxAg only in tumor tis-sues or in adjaeent nontumor tissues were 24% and16%. HBsAg was detected in 16% of cases in tumortissues and 74% in suirounding nontumor tissues. InCAH samples, the positive rates of HBxAg andHBsAg were 6.6% and 73.3%. HBcAg was only de-tected in nontumor suirounding liver tissues, the posi-tive rates being 18% . In CAH samples, no HBcAg wasdetected. The results showed that HBxAg is a commonmarker in liver tissue from patients with HBVrelatedHCC. The findings of HBxAg in the absence ofdeteetable HBsAg and HBcAg in the liver tissues suggested that HBxAg could be independent of HBVreplication and implied that the synthesis of HBxAgmay be directed from integrated HBV DNAtemplates. It is possible to use antiHBx monoclonalantibody as a carrier for the targeting therapy ofHCC.